Eli Lilly reported Phase 2 results showing its amylin receptor agonist eloralintide produced substantial weight loss, with some arms showing mean reductions comparable to leading GLP‑1 therapy and an improved gastrointestinal tolerability profile. The company said it will initiate a Phase 3 program based on the data presented at ObesityWeek 2025. Phase 2 cohorts saw mean weight losses ranging up to roughly double‑digit percentages versus placebo, and Lilly highlighted fewer GI adverse events compared with historical standards for incretin‑based agents. The data position amylin as a competitive modality in the next wave of anti‑obesity therapeutics, alongside other amylin and dual‑agonist programs from peers. Investors and competitors will monitor Phase 3 design and enrollment targets; payers and clinicians are evaluating where amylin drugs could sit within expanding obesity treatment algorithms and cost frameworks.